Trial reportArchives of disease in childhood2001
Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial.
Trial report in Archives of disease in childhood, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Pooled it
- Guidelines on the use of extracorporeal photopheresis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2014Guideline
- Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.Diabetologia · 2011Trial
- Effect of photopheresis on lymphocyte population in children with newly diagnosed type 1 diabetes.Clinical and diagnostic laboratory immunology · 2004Trial
- European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Extracorporeal Photopheresis-An Overview.Frontiers in medicine · 2018Review
- Photopheresis: Advances and Use in Systemic Sclerosis.Current rheumatology reports · 2017Review
- Ultraviolet Irradiation of Blood: "The Cure That Time Forgot"?Advances in experimental medicine and biology · 2017Review
- Ultraviolet blood irradiation: Is it time to remember "the cure that time forgot"?Journal of photochemistry and photobiology. B, Biology · 2016Review
- Review
- Diosgenin and 5-Methoxypsoralen Ameliorate Insulin Resistance through ER-α/PI3K/Akt-Signaling Pathways in HepG2 Cells.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Extracorporeal photopheresis as a therapy for autoimmune diseases.Journal of clinical apheresis · 2015Review
- Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.Therapeutic advances in hematology · 2013Article
- Immune intervention in children with type 1 diabetes.Current diabetes reports · 2010Article
- Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells.Apoptosis : an international journal on programmed cell death · 2010Review
- The role of immunomodulation therapy in autoimmune diabetes.Journal of diabetes science and technology · 2009Review
- Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children.Clinical and experimental immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years photopheresis, an extracorporeal form of photochemotherapy using psoralen and ultraviolet A irradiation of leucocytes, has been claimed to be an effective form of immunomodulation.
aimTo evaluate its effect in type 1 diabetes we performed a double blind, controlled study using placebo tablets and sham pheresis in the control group.
methodsA total of 49 children, aged 10-18 years of age at diagnosis of type 1 diabetes were included; 40 fulfilled the study and were followed for three years (19 received active treatment with photopheresis and 21 placebo treatment).
resultsThe actively treated children secreted significantly more C peptide in urine during follow up than control children. C peptide values in serum showed corresponding differences between the two groups. The insulin dose/kg body weight needed to achieve satisfactory HbA1c values was always lower in the photopheresis group; there was no difference between the groups regarding HbA1c values during follow up. The treatment was well accepted except for nausea (n = 3) and urticaria (n = 1) in the actively treated group. There were no differences regarding weight or height, or episodes of infection between the two groups during follow up.
conclusionPhotopheresis does have an effect in addition to its possible placebo effect, shown as a weak but significant effect on the disease process at the onset of type 1 diabetes, an effect still noted after three years of follow up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.